Text Size

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
OSMOS Clinical Research, Inc
PSI Pharma Support Intl
Nextrials, Inc.
eResearch Technology, Inc.
Hoffmann-La Roche
ACM Pivotal Global Central Laboratory
Information provided by:
Generex Biotechnology Corp.
ClinicalTrials.gov Identifier:
NCT00668850
First received: April 24, 2008
Last updated: June 6, 2011
Last verified: June 2011
History of Changes
  Purpose

To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy.


Condition Intervention Phase
Diabetes Mellitus
 Drug: Generex Oral-lyn™
Drug: Regular human insulin
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Generex Biotechnology Corp.:

Primary Outcome Measures:
  • To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH intermediate acting insulin therapy [ Time Frame: change in HbA1c from the Day 0 (V3) to Day 180 (V9) of Treatment Phase. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety, tolerability, and satisfaction with Generex Oral-lyn™ therapy when administered by the RapidMist™ Diabetes Management System [ Time Frame: 26 week ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 500
Study Start Date: April 2008
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
 Drug: Generex Oral-lyn™
Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
Other Name: buccal Insulin spray
Active Comparator: 2
Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
 Drug: Regular human insulin
Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
Other Name: insulin

Detailed Description:

This is a 26 week open-label, randomized, multi-center, active comparator study to compare oral spray insulin (Generex Oral-lyn™) with regular human insulin therapy as measured by HbA1c, and number of hypoglycaemic episodes in type-1 diabetes mellitus subject. All subjects will be on BID NPH intermediate acting insulin therapy. If subject is using long acting insulin (Glargine, Detemir, etc.), he/she must be switched to NPH intermediate acting insulin. If on insulin analogue (Novolog, Lispro, Aspart, Aphidra, Glulisine, or any other analogue available in the subject's geographical area), the subject must be switched to regular human insulin 3 times a day.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be male or female between the ages 18 to 75 years
  • Type 1 diabetes mellitus patients (according to ADA and/or WHO classification) who have >1 year history of type 1 DM and are currently managed with daily insulin injections totalling 0.3 to 0.8 IU/kg of body weight;
  • Current physical examination, vital signs and ECG at screening that reveals no clinically significant abnormalities;
  • Have a body mass index (BMI) <27;
  • 8.5% (inclusively)<Have a glycosylated haemoglobulin HbA1c
  • Willing and able to follow the American Diabetes Association diet guidelines for type 1 diabetes; be able to commit to perform home blood glucose monitoring and record values as well as hypoglycemic events
  • Willing to give written informed consent prior to admission into the study.

Exclusion Criteria:

  • Have a significant active asthma or suspected abnormalities of buccal mucosa; cardiovascular, cerebrovascular, hepatic, renal, gastrointestinal, hematological, or auto-immune disease (other than auto-immune thyroid disease); history of athopy or drugs allergy
  • Have evidence of unstable retinopathy (defined as pre-proliferative or proliferative retinopathy currently requiring photocoagulation therapy), nephropathy or neuropathy (gastroparesis or orthostatic hypotension);
  • Have hypoglycemia unawareness;
  • Have had more than one episode of severe hypoglycemia with seizure or coma or ketoacidosis within the past 12 months;
  • Have a blood pressure in excess of 160/100 mmHg at the Screening visit;
  • Have had any acute illness within the 2 weeks prior to screening;
  • Have a history of drug or alcohol abuse that in the opinion of the Investigator would interfere with participation in the protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00668850

  Show 74 Study Locations
Sponsors and Collaborators
Generex Biotechnology Corp.
OSMOS Clinical Research, Inc
PSI Pharma Support Intl
Nextrials, Inc.
eResearch Technology, Inc.
Hoffmann-La Roche
ACM Pivotal Global Central Laboratory
Investigators
Study Chair: Gerald Bernstein,, MD Generex Biotechnology Corp.
Study Director: Jaime Davidson, MD Generex Biotechnology Corp.
Principal Investigator: Philip Raskin, MD University of Texas Southwestern Medical Center at Dallas
  More Information

No publications provided

Responsible Party: George E. Markus, Generex Biotechnology Corp.
ClinicalTrials.gov Identifier: NCT00668850     History of Changes
Other Study ID Numbers: GEN-084-OL
Study First Received: April 24, 2008
Last Updated: June 6, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
 Immune System Diseases
Insulin
Insulin, NPH
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013